Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma

A lingering criticism of radioimmunotherapy in non-Hodgkin lymphoma is the use of cold anti-CD20 antibody along with the radiolabeled anti-CD20 antibody. We instead combined radioimmunotherapy with immunotherapy targeting different B-cell antigens. We evaluated the anti-CD22 90Y-epratuzumab tetraxet...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Thomas E. Witzig, Michael B. Tomblyn, Jamal G. Misleh, Ebenezer A. Kio, Robert M. Sharkey, William A. Wegener, David M. Goldenberg
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Ferrata Storti Foundation 2014-11-01
Reeks:	Haematologica
Online toegang:	https://haematologica.org/article/view/7203
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!